Abstract:Abstract Background During the early stages of Alzheimer’s disease (AD), patients often suffer from prodromal symptoms such as anxiety, impulsivity, depression, agitation, and sleep disturbances prior to the onset of cognitive impairment. Incidentally, the brainstem noradrenergic locus coeruleus (LC) is the first structure to develop hyperphosphorylated ‘pretangle’ tau pathology in the human brain. Furthermore, norepinephrine (NE) influences several physiological processes such as sleep/wake cycle, arousal, stress, mood, and attention which have been implicated in the prodromal behavioral abnormalities. While clinical studies show significant correlations between LC dysfunction and neuropsychiatric symptoms, a causal relationship between early tau accumulation in the LC and the manifestations of prodromal behaviors remains to be resolved. To explore this, we developed a translationally‐relevant tau mouse model that recapitulates the ‘LC first’ phenomena commonly observed in humans. Method Adult male and female tyrosine hydroxylase (TH)‐Cre mice aged 4 months underwent intra‐LC infusions with a Cre‐dependent adeno‐associated virus (AAV) expressing mCherry, wild‐type (WT) human tau or P301S mutant human tau (n = 3/group). 3 months post‐infusion, mice underwent a panel of behavioral tests to assess sleep latency, locomotor activity, compulsivity, stress‐induced anxiety‐like behavior, association memory deficits, impulsivity, and attentional impairments. Following behavioral tests, brain sections comprising the LC, hippocampus and prefrontal cortex (PFC) were immunostained with TH to assess for LC integrity, AT8 to detect pretangle tau, NE transporter (NET) to evaluate NE fiber intensity in projection regions, and GFAP and IBA1 to identify neuroinflammatory markers. Immunoreactivity (IR) will be calculated as a measure of fluorescence via ImageJ. Result It has been proposed that tau accumulation in the LC may provoke mild to moderate damage in LC neurons, triggering compensatory mechanisms such as LC hyperactivity. It is hypothesized that at 3 months, LC‐specific tau pathology will result in hyperarousal, compulsivity, anxiety‐like behavior, and impulsivity. In tandem, human tau‐expressing mice are expected to display increased TH, reflecting LC hyperactivity, neuroinflammatory markers and reductions in NE fibers in LC‐projecting regions. These findings will be presented in July 2023. Conclusion This research will elucidate the role of LC in governing prodromal symptoms. Further studies will be needed to assess molecular mechanisms underlying tau‐mediated LC dysfunction in early AD.

Pathological tau alters head direction signaling and induces spatial disorientation

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Altered patterning of neural activity in a tauopathy mouse model

Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology

Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer’s disease

Expression of P301L-hTau in Mouse MEC Induces Hippocampus-Dependent Memory Deficit

Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss

Olfactory Deficit is Associated with Mitral Cell Dysfunction in the Olfactory Bulb of P301S Tau Transgenic Mice.

Early and selective localization of tau filaments to glutamatergic subcellular domains within the human anterodorsal thalamus

Alzheimer‐like tau accumulation in dentate gyrus mossy cells induces spatial cognitive deficits by disrupting multiple memory‐related signaling and inhibiting local neural circuit

Behavioral and Neurophysiological Implications of Pathological Human Tau Expression in Serotonin Neurons

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

Path integration deficits are associated with phosphorylated tau accumulation in the entorhinal cortex

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer’s disease

Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction

Consequences of Pathogenic Tau Expression in Mouse Locus Coeruleus

Wolframin-1-expressing neurons in the entorhinal cortex propagate tau to CA1 neurons and impair hippocampal memory in mice

Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy

Tau pathology in the dorsal raphe may be a prodromal indicator of Alzheimer's disease

Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau in vivo .